ReviewBritish journal of biomedical science2025
Mitochondrial DNA Mutations and Epigenetic Regulation in Type 2 Diabetes Mellitus Development.
Review in British journal of biomedical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global prevalence of type 2 diabetes mellitus (T2DM) has increased significantly over the past decade and is projected to rise further. While genetic and lifestyle factors are well-established contributors to T2DM pathogenesis, mitochondria have also gained attention as the key players. Many studies suggested that mitochondrial DNA (mtDNA) mutations and epigenetic modifications were implicated in the development and progression of T2DM. This review aimed to provide a comprehensive analysis of mtDNA mutations and epigenetic modifications associated with T2DM. Based on data from 30 published studies, a total of 117 mtDNA mutations were identified to be associated with T2DM, with D-loop region being the mutation hotspot. However, it was reported that the majority of D-loop mutations were also more frequently observed in healthy populations compared to mutations in other mtDNA regions, suggesting their potential non-pathogenic characteristic. Thus, mtDNA mutations found to be associated with T2DM but with lower occurrence in healthy populations may play a more significant role in influencing T2DM susceptibility. Regarding epigenetic modifications, mtDNA methylation was commonly reported in the D-loop and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.